MELBOURNE, Australia, and PRINCETON, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Opthea and sozinibercept will be highlighted during two upcoming Ophthalmology conferences.
Conference details are as follows:
The 17th Congress of the Asia-Pacific Vitreo-Retina Society (APVRS)
| Session: | Rapid Fire 4 – Retina (Medical & Surgical) | |
| Timing: | Friday, November 22, 2024, 3:15 – 3:20 PM Singapore time (GMT+8) | |
| Presentation: | Intravitreal Sozinibercept (anti-VEGF-C/-D ‘trap’) Combined with Ranibizumab for the Treatment of Polypoidal Choroidal Vasculopathy: A Predefined Phase 2b Subgroup Analysis | |
| Presenter: | Gregg T. Kokame, MD, MMM, FASRS | |
| Abstract: | https://2024.apvrs.org/abstract/?code=200963 |
Gregg T. Kokame, MD, MMM, FASRS, will present data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured at 24 weeks. Data from this subgroup show that patients treated with a combination of sozinibercept and ranibizumab experienced significantly better visual and anatomic outcomes compared to ranibizumab alone.
APVRS, themed Transforming Retinal Disease Management with Technology, gathers a distinguished international faculty of top specialists in vitreo-retina to share their expertise and experience. The scientific program will focus on exciting areas such as novel surgical innovations
and therapies, and latest advances in imaging and research.
Ophthalmology Innovation Summit XIV (OIS)
| Session: | Retina Innovation Showcase | |
| Timing: | Saturday, November 23, 2024, 11:15 AM – 12:50 PM PT | |
| Presenter: | Frederic Guerard, PharmD, CEO, Opthea | |
| Agenda: | https://ois.net/ois-xiv-agenda/ |
The Ophthalmology Innovation Summit connects clinical, corporate, and capital leaders to drive the ophthalmic market forward. It showcases groundbreaking advancements and clinical insights in both anterior and posterior ophthalmology segments and offers the opportunity to learn, network and collaborate.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Web: www.opthea.com
| Last Trade: | US$3.34 |
| Daily Change: | 0.11 3.41 |
| Daily Volume: | 15,669 |
| Market Cap: | US$513.990M |
December 19, 2024 November 26, 2024 November 15, 2024 October 10, 2024 September 18, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
